ProMIS NeurosciencesのROCE
ProMIS NeurosciencesのROCEは何ですか。
ProMIS Neurosciences, Inc.のROCEは0.00%です。
ROCEの定義は何ですか。
使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
TSXのセクタHealth CareにおけるROCEの企業と比べるProMIS Neurosciences
ProMIS Neurosciencesは何をしますか。
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
ProMIS Neurosciencesと類似のroce
- Omega Alpha SpacのROCEは-0.01%です。
- The GapのROCEは-0.01%です。
- Elemental Royalties LtdのROCEは-0.01%です。
- Auburn National BancorpのROCEは-0.01%です。
- Galaxy DigitalのROCEは-0.01%です。
- The GapのROCEは-0.01%です。
- ProMIS NeurosciencesのROCEは0.00%です。
- Tejon Ranch CoのROCEは0.01%です。
- Glen Burnie BancorpのROCEは0.02%です。
- MSP Steel & PowerのROCEは0.02%です。
- TTL Beteiligungs- und Grundbesitz-AGのROCEは0.03%です。
- First Foundation IncのROCEは0.03%です。
- FirstMark Horizon AcquisitionのROCEは0.03%です。